Conditional protein splicing of α-sarcin in live cells

Spencer C. Alford,†a Connor O’Sullivan,†a Jon Obst, b Jennifer Christie ab and Perry L. Howard*abc

Protein splicing technology harnesses the ability of inteins to ligate protein fragments, forming a mature protein. This report describes our effort to engineer rapamycin-dependent protein splicing of a ribotoxin, called α-sarcin. Engineering this system required the investigation of important splicing parameters, including extein context and splicing temperature. We show α-sarcin splicing is dependent on rapamycin, is inducible with rapid kinetics, and triggers apoptosis in HeLa cells. These findings establish a proof-of-concept for a conditional cell ablation strategy.

Introduction

Selective cell ablation at key stages of development is an important strategy used to address questions related to cell autonomy, lineage, and tissue regeneration.1–4 The strategy is also relevant for therapeutic interventions, such as eliminating tumor and transplanted cells.5–9 In each of these examples, cell ablation can be achieved through regulated expression of a suicide gene in a specific population of cells using tissue-specific or inducible promoters. However, this approach is limited by slow induction of cell ablation, which prevents the investigation of many developmental questions. Greater temporal control can be achieved through the use of pro-drug converting enzymes, such as herpes simplex thymidine kinase or cytosine deaminase.9 These enzymes activate a pro-drug to trigger cell death, and the timing is controlled by addition of the pro-drug. However, the action of many drugs created by these enzymes requires actively dividing target cells.9 Other cell ablation strategies, such as expression of bacterial nitroreductase and pro-drug CB1954/MTZ, are able to kill non-dividing cells, but require high levels of enzyme expression.10 These enzymes activate a pro-drug to trigger cell death, and the timing is controlled by addition of the pro-drug. However, the action of many drugs created by these enzymes requires actively dividing target cells.9 Other cell ablation strategies, such as expression of bacterial nitroreductase and pro-drug CB1954/MTZ, are able to kill non-dividing cells, but require high levels of enzyme expression.10 Therefore, an efficient inducible cell ablation method that rapidly eliminates both dividing and non-dividing cells is desirable. In this study, we determined whether conditional protein splicing could be used as a strategy to tightly regulate cell ablation.

Conditional protein splicing utilizes inteins, which are self-excision protein sequences that remove themselves from a precursor protein and concurrently splice together flanking protein sequences, called exteins11 This process can be used to regulate protein function in live cells with rapid kinetic resolution.11 Splicing typically requires two sequence determinants: a cysteine or serine within the intein sequence at the N-terminal intein–extein splice junction, and a histidine–asparagine dipeptide sequence at the C-terminal intein–extein splice junction, immediately followed by a cysteine, serine, or threonine as the first C-terminal extein residue.12 Flanking residues within the N-terminal and C-terminal extein sequences also influence splicing efficiency,13,14 and many inteins can accommodate a variety of extein sequences and still splice effectively.15,16 Intein activity may also be regulated by changes in structure and folding. Some inteins occur naturally as split trans-splicing elements, and alternatively, cis-splicing inteins can be artificially split by recombinant methods.17,18 Splicing mediated by split inteins is contingent on reconstitution of the native intein-fold upon re-association of the intein fragments. By fusing split intein fragments with low re-association affinities to protein (hetero)dimerization domains, splicing becomes conditional on the addition of a dimerizing agent and the consequent re-association of intein fragments.11,19 Two such varieties of conditional protein splicing have been described for splicing proteins in cultured mammalian cells: an estrogen receptor-hydroxytamoxifen system20,21 and an FKBP-rapamycin–FRB system.11,19 Examples of spliced functional proteins in physiological systems have largely been limited to reporter proteins (e.g., luciferase or GFP).11,19,22–25 To date, demonstrations of splicing non-reporter proteins in live cells has been limited20,26,27 and the approach has not been adapted for cell ablation studies. Several limitations have slowed the broad applicability of protein splicing, including a minimum requirement for a naturally occurring (or artificially installed) cysteine, serine, or threonine at the C-terminal intein–extein splice junction, as well as the possible requirement of installing splicing-permissive

* Centre for Biomedical Research, University of Victoria, P.O. Box 3020 Station CSC Victoria, BC, Canada V8W 3N5. E-mail: phoward@uvic.ca
† Department of Biochemistry/Microbiology, University of Victoria, P.O. Box 3020 Station CSC Victoria, BC, Canada V8W 3N5
‡ Department of Biology, University of Victoria, P.O. Box 3020 Station CSC Victoria, BC, Canada V8W 3N5
†† These authors contributed equally to this work.
exon mutations that may destabilize or inactivate the spliced target protein.\textsuperscript{15,26} We investigated each of these limitations while developing our splicing-mediated cell ablation method.

We envisioned a strategy in which the cytotoxicity of a protein toxin is regulated by protein splicing, such that addition of a dimerizing agent rapidly activates the toxin. The ability to inducibly trigger toxin activity should be valuable in genetic, developmental, and therapeutic studies where one wants to eliminate specific cells with precise temporal and spatial resolution. To test our concept, we chose a ribonuclease named \( \alpha \)-sarcin, which is cytotoxic to many tumor cell lines as well as dividing and non-dividing cells.\textsuperscript{28–30} Using rational design and molecular biology, we recombinantly split \( \alpha \)-sarcin into non-toxic fragments and generated a system to splice the fragments together upon addition of rapamycin. Our demonstration of conditional splicing of \( \alpha \)-sarcin adds to the limited number of proteins effectively spliced together in live cells and serves as a proof-of-concept for a conditional cell ablation strategy.

Materials and methods

Molecular biology and construct design

All restriction enzymes, DNA polymerase, and DNA ligase were purchased from New England Biolabs. The \( \alpha \)-sarcin gene was initially assembled by annealing complimentary oligonucleotides (Operon) and was subsequently used as a template to PCR amplify its gene fragments. Desired splice junctions were generated by overlap extension PCR and full-length gene fusions, X-VMAN-FKBP and FRB-VMAN-Y were cloned into pcDNA3 plasmids via BamHI/Xhol and HindIII/Xhol, respectively (\( X = \) NSAf, NGFP, or MBP; \( Y = \) CSar, CGFP, or polyHis). All constructs were verified by sequence analysis.

Cell culture and transfections

HeLa cells were grown in DMEM supplemented with 10% FBS and penicillin/streptomycin (100 \( \mu \)g ml\(^{-1}\) each) at 37 °C and 5.0% CO\(_2\). Cells were seeded at a density of 3.0 \( \times \) 10\(^5\) cells per well on 6-well plates. After 24 hours, transfections were performed with designated plasmids using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions. Transfected cells were treated with 10 nM rapamycin (unless otherwise stated) or DMSO, 24 hours post transfection. After rapamycin addition, cells were incubated at 30 °C for 12 hours before being processed for induction of apoptosis.

Immunoblotting

Whole cell lysates were prepared with 1 \( \times \) SDS-PAGE sample buffer (62.5 mM Tris pH 6.8, 2% (w/v) SDS, 75 mM DTT, 7.5% glycerol, 0.02% bromophenol blue) and heated at 95 °C for ten minutes prior to electrophoresis. Protein samples were resolved through 11% SDS-PAGE gels and transferred to nitrocellulose membranes (0.45 \( \mu \)m) using transfer buffer (25 mM Tris pH 8.3, 192 mM glycine, 20% (w/v) methanol). Anti-GFP (Roche), anti-FLAG (Stratagene), and anti-\( \beta \)-actin antibodies (Sigma) were used at working dilutions of 1 : 4000 or 1 : 5000. Anti-mouse IgG horseradish peroxidase was used as a secondary antibody/detection system (R and D systems) at a working dilution of 1 : 8000 to 1 : 10 000. Proteins were detected using an enhanced chemiluminescence immunoblotting detection system (Amersham). Blots were exposed to film and developed using an automated X-ray film developer. Lysate from HeLa cells expressing a non-toxic 3xFLAG-sarcin was used as an electrophoretic mobility standard for spliced 3xFLAG-sarcin.

Cell viability assay

HeLa cells were seeded at 2.0 \( \times \) 10\(^4\) cells per well in a 24-well dish and allowed to grow for 24 hours. Transient transfections were performed using Lipofectamine 2000 (Invitrogen). Empty plasmid (pcDNA3.1) was added to the transfection mix to maintain the total DNA concentration per transfection at 500 ng per transfection. 48 hours after transfection, cell viability was assayed. HeLa cells were washed once with phosphate buffered saline and fixed with 10% formalin for 10 minutes at room temperature. Cells were washed two times with \( \text{dH}_2\text{O} \) and incubated with 0.1% crystal violet for 30 minutes at room temperature. To remove excess stain, cells were washed with \( \text{dH}_2\text{O} \). Crystal violet was extracted using 10% acetic acid. Extracts were diluted 1 : 4 and their absorbance was measured at 595 nm using a Victor\textsuperscript{V} 1420 Multilabel plate reader. Percent viability was determined as the ratio of \( A_{350\text{nm}} \) of toxin-transfected cells to the \( A_{350\text{nm}} \) of the pcDNA 3.1 transfected control cells. Experiments were performed in triplicate.

Apoptosis assay

Apoptosis assays were performed using an annexin V-FITC apoptosis Kit (BD Biosciences) and cytometric analysis was conducted on a BD FACSCalibur cytometer. 2.0 \( \times \) 10\(^4\) events per sample were acquired using Cell Quest Software (BD Biosciences) and analyzed using FlowJo Software. Data represents the average annexin V positive population for each of the conditions from 5 independent experiments, each performed in triplicate.

Transfection and splicing efficiency

24 hours after transfection with either full length GFP or GFP splice constructs, 2.0 \( \times \) 10\(^4\) cells were analyzed on a BD FACSCalibur flow cytometer and GFP intensity was quantified. Full length GFP-transfected cells and cells containing successfully spliced GFP were identified by comparison to untransfected cells.

Luciferase assay

8.0 \( \times \) 10\(^3\) C2C12 cells per well were seeded on a 96-well plate and 24 hours later, cells were transfected with a plasmid encoding luciferase (pMiR-Luc-Control), and either pcDNA3.1 or \( \alpha \)-sarcin constructs as indicated. 4 hours later, samples were treated with 5 nM rapamycin or DMSO, and incubated at 30 °C for 12 hours. The dual-luciferase reporter assay system (Promega) was used according to the manufacturer’s instructions, and luminescence was measured using a Perkin Elmer Victor\textsuperscript{V} 1420 multilabel plate counter. Percent relative translation inhibition was calculated as [1 - (Luc\text{cap}/Luc\text{DMSO})] \times 100.
qRT-PCR

$2.0 \times 10^5$ C2C12 cells per well were seeded on a 6-well plate and transfected after 24 hours with constructs 2 and 9 as well as pMiR-Luc-Control. 4 hours later, samples were treated with 5 nM rapamycin or DMSO, and incubated at 30 °C for 12 hours. RNA was extracted using direct-zol (Zymo Research), cDNA was synthesized using random primers with the high capacity cDNA reverse transcription kit (Life Technologies), and transcripts were amplified using Ssofast EvaGreen Supermix (Bio-Rad) on a Stratagene MX3000P qPCR system. Firefly luciferase cDNA was amplified using the primers 5'-CTCACTGAGACTCAGCAGC-3' and 5'-TCCAGATCCACAACCTTCG-3'. GAPDH was amplified using the primers 5'-ACGACCCCTTCATTGACCTC-3' and 5'-GTCTGCCTCTCGAAATGG-3'. Relative mRNA fold change was calculated as $2^{\Delta \Delta Ct Luc(rap-DMSO)/2^{\Delta \Delta Ct GAPDH(rap-DMSO)}}$.

Results

To test whether conditional protein splicing could be used to produce α-sarcin inside mammalian cells, we generated 3-part splicing constructs. First, we cloned the α-sarcin N-terminal fragment (NSar, amino acids 1–27) in frame with the N-terminal VMA intein fragment (VMA N) (Fig. 1A and B). Second, the C-terminal fragment of α-sarcin (CSar, amino acids 28–150) was cloned in frame with the C-terminal VMA intein fragment (VMA C) (Fig. 1A and B). The VMA N and VMA C fragments were, in turn, fused to either the FK506-binding protein (FKBP) or the FK506-rapamycin binding domain of mTor (FRB), respectively.11 (Fig. 1B). The splicing constructs were designated NSar-VMA N-FKBP and FRB-VMA C-CSar. In addition, we introduced an N28C mutation into the CSar fragment at the intein splice junction to satisfy the chemical requirements for VMA splicing. Before proceeding, we tested whether the N28C cysteine splicing 'scar' would affect α-sarcin toxicity by expressing a full-length N28C α-sarcin mutant in cultured mammalian cells. Expression of the N28C mutant in HeLa cells displayed similar toxicity to wild type α-sarcin, indicating this mutation is tolerated and not detrimental to function (Fig. 2A). Since the N28C product retains cytotoxicity, we next tested whether our designed constructs were able to splice full-length α-sarcin.

We predicted the splicing constructs, NSar-VMA N-FKBP and FRB-VMA C-CSar, would not be toxic when expressed independently or when co-expressed. However, after addition of rapamycin, the VMA intein should reconstitute and splice NSar and CSar fragments together, forming functional α-sarcin (Fig. 1B). We expressed NSar-VMA N-FKBP with an N-terminal 3xFLAG tag (Fig. 1C, construct 1). This enabled immunoblot detection of the precursor as well as any splicing end products. Splicing between construct 1 and FRB-VMA C-CSar (Fig. 1C, construct 2) was thus expected to produce 3xFLAG tagged α-sarcin. Constructs 1 and 2 were expressed in HeLa cells and treated with rapamycin at 37 °C. Construct 1 was readily detected (at 47 kDa) by immunoblot analysis of cell lysates, as were self-cleavage products at 30 and 20 kDa. However, we were unable to detect spliced 3xFLAG α-sarcin in rapamycin-treated cells (Fig. 2B). We speculated the lack of splicing was attributed to a non-optimal incubation temperature.

The VMA intein demonstrates increased splicing activity at temperatures below 37 °C. Therefore, we lowered the incubation temperature of our experiments to 30 °C to determine if the elevated temperature of cultured mammalian cells (37 °C) was preventing α-sarcin splicing (Fig. 2B). Even at the reduced temperature we did not detect any spliced product. To confirm the split VMA intein was functional, we generated splicing constructs comprising split green fluorescent protein (GFP) fragments. An N-terminal fragment of GFP (1–128) was fused to VMA N-FKBP (Fig. 1C, construct 3) and the C-terminal fragment (129–238) was fused to FRB-VMA C-CSar (Fig. 1C, construct 4). The GFP split site, between residues 128 and 129, falls at the end of strand 6 and has previously been shown amenable to intein-mediated splicing in vitro. To facilitate splicing we introduced H129C and E125I mutations, as previously described. Using constructs 3 and 4, GFP fluorescence was readily visible in the presence of rapamycin at the reduced temperature of 30 °C, whereas no fluorescence was detected at 37 °C (Fig. 2C). Splicing of full length GFP was confirmed by immunoblot analysis using an anti-GFP antibody. Although the amount of spliced product compared to the amount of precursor is low, the detection of this band following SDS-PAGE
indicates the fluorescence is likely from the spliced GFP protein (Fig. 2D) and not merely protein complementation of the GFP fragments. Analysis of cell lysates showed background fluorescence associated with construct 4, which contains the C-terminal fragment of GFP (Fig. 2E). We detected fluorescence associated with construct 4 by flow cytometry, but it was not visible by fluorescence microscopy (Fig. 2C). Importantly, this background signal does not increase when construct 3 is co-expressed in the absence of rapamycin, indicating fluorescence is dependent on rapamycin and splicing (Fig. 2E). Together, these results indicated the VMA intein (in the context of GFP and α-sarcin) splices poorly at 37 °C, and the intein-α-sarcin splice junctions interfere with splicing.

To investigate the α-sarcin extein context at the splice junctions, we used splicing constructs 5 and 6 (Fig. 1C), which are comprised of Maltose binding protein (MBP) fused to VMA N-FKBP and a poly-Histidine (polyHis) sequence fused to FRB-VMA C, respectively. These splicing constructs were used in the first demonstration of conditional protein splicing. As expected, we readily detected splicing of MBP to polyHis (Fig. 3A). We next attempted to splice MBP to the CSar fragment (using constructs 5 and 2, Fig. 1C) to determine whether the C-terminal splice site within α-sarcin was functional. The CSar fragment readily spliced to MBP, indicating the splicing defect was likely within the NSar extein (Fig. 3B). To test this, we generated construct 7 (Fig. 1C), in which the NSar fragment is fused to the VMA N through a 5 amino acid linker identical in sequence to the splicing-permissive linker joining MBP and VMA N in construct 5. Under these conditions, the 3xFLAG NSar fragment was spliced to the CSar fragment after rapamycin addition, and resulted in a slightly higher migrating band (> 25 kDa) as expected from the additional amino acids provided by the linker (Fig. 3C). Therefore, the extein sequence context contributed by the native NSar fragment is not suitable for splicing. Unfortunately, inserting the construct 5 linker sequence into α-sarcin significantly attenuated its toxicity, rendering it unsuitable for our purposes (Fig. 2A).

Based on the above results, we designed a modified NSar extein, in which we eliminated the linker sequence, but introduced a mutation at the NSar residue immediately preceding the intein sequence (designated as the −1 position). We hypothesized the native glutamine found at this position in α-sarcin interferes with splicing and mutating it to glycine, as found in the linker, would improve splicing. We first tested whether a full-length α-sarcin Q27G mutant (plus N28C) would retain cytotoxicity as a splicing end product. Introduction of Q27G/N28C into α-sarcin did not affect its cytotoxicity when expressed in HeLa cells (Fig. 2A). Therefore, Q27G was incorporated into the NSar fragment to generate construct 8 (Fig. 1C). In cells transfected with constructs 2 and 8, rapamycin treatment resulted in the production of a spliced product at ~ 23 kDa which co-migrated with a full-length 3xFLAG-α-sarcin electrophoretic standard (Fig. 3D). We generated this standard by directly expressing full length 3xFLAG-sarcin from a plasmid in HeLa cells and lysing the cells under identical conditions used in the splicing experiments. Although a faint band at the same size was detected in cells treated with DMSO (Fig. 3D), it was not detected in subsequent experiments (Fig. 3E and F and data not shown), and we conclude it was cross contamination between
Expression of α-sarcin in the cytoplasm of HeLa cells induces apoptosis.\textsuperscript{11} However, the addition of an N-terminal 3xFLAG tag on α-sarcin significantly attenuates its cytotoxicity (Fig. 2A).\textsuperscript{32} This feature permitted immunoblot characterization, but was not amenable for cell ablation. To address this, we generated construct 9, (Fig. 1C) which contained an untagged NSar Q27G fragment, and determined whether the levels of spliced α-sarcin were sufficient to kill cells. HeLa cells were co-transfected with constructs 2 and 9 and were incubated with 10 nM rapamycin, or DMSO. After 12 hours at 30 °C, cell viability was assayed. As shown in Fig. 4A and B, the addition of rapamycin, but not DMSO, induced apoptosis. Approximately 25% of the cells treated with rapamycin were apoptotic. Since the overall transfection efficiency was 36%, as determined by GFP expression (Fig. 2E), an approximate 70% ablation efficiency of transfected cells was obtained. This level of apoptosis was not obtained when either constructs 2 or 9 were expressed individually with rapamycin, or when the constructs were co-expressed in the absence of rapamycin. Nor was the toxicity associated with expression of constructs 2 or 9, individually or together, above the apoptosis seen with the GFP splicing constructs (Fig. 4A and B). The efficiency of apoptosis induction (Fig. 4B) and GFP fluorescence (Fig. 2E) were similar. This suggests that in cells not undergoing apoptosis, the lack of cell death is related to poor folding and stability of the intein constructs and not α-sarcin resistance. To further support the induction of apoptosis we observed was due to production of α-sarcin, we tested whether we could detect inhibition of protein translation that characteristically accompanies α-sarcin activity in cells. The toxicity of α-sarcin is linked to its ribonucleolytic action on 28S rRNA, which stops protein synthesis, and leads to apoptosis. To confirm spliced α-sarcin inhibited protein synthesis, we measured the production of a luciferase reporter after triggering splicing. Co-expression of constructs 2 and 9 inhibited luciferase production after rapamycin treatment (Fig. 4C). No change in mRNA levels of the reporter were detected following rapamycin treatment (Fig. 4D), confirming the decrease in luciferase activity was due to protein synthesis inhibition. In summary, the fact that with a single amino acid change to the NSar extein, a rapamycin-induced FLAG-tagged product was detected by immunoblotting and migrated at precisely the same size as 3xFLAG-sarcin, supports that this was a splicing product and not the result of cleavage and/or degradation. Furthermore, this conclusion is supported by the rapid kinetics and dose dependency of product production.\textsuperscript{11} The trademark protein synthesis inhibition and accompanying induction of apoptosis seen with constructs 2 and 9 solely in the presence of rapamycin argues the observed cytotoxicity is due to correct splicing of α-sarcin. Taken together, our results show that cytotoxicity of α-sarcin can be regulated by conditional protein splicing.

**Discussion**

Our report describes the conditional protein splicing of a protein toxin, α-sarcin, in mammalian cells. We showed that
by introducing two mutations, which do not affect cytotoxicity, \( \alpha \)-saracin can be split in two non-toxic fragments and quickly reassembled through rapamycin-mediated protein splicing in live cells. This has several advantages for cell ablation studies. First, \( \alpha \)-saracin is toxic in low amounts.\(^{28,29}\) Indeed, although we could not detect the untagged \( \alpha \)-saracin by immunoblot (data not shown), its cytotoxicity was still evident. Therefore, high efficiency splicing is not required. Second, \( \alpha \)-saracin induces apoptosis, in part, by inactivating the ribosome and inhibiting protein synthesis, and is toxic to both dividing and non-dividing cells. Therefore, this ablation strategy is applicable to situations where targeting post-mitotic or quiescent populations is desired. Third, the timescale required for \( \alpha \)-saracin splicing is rapid. Compared to conventional promoter-driven expression, which typically requires 6–8 hours before protein can be detected by immunoblotting, spliced \( \alpha \)-saracin was produced within 10 minutes. Together, the low dose of rapamycin required and the low background splicing should allow researchers to better study kinetic and developmental questions. Although these features are advantageous, our investigation revealed important design considerations and potential obstacles.

Fortunately, our study showed these obstacles can be overcome with molecular engineering. Identifying proteins amenable to splicing and choosing appropriate splice sites relies largely on informed guesses based on protein structures and empirical testing of several splice sites. Choosing splice sites that lie between defined domains is not possible when the target protein lacks distinct domains or is comprised of a single domain. Using its solution structure as a guide,\(^{33}\) we chose to split \( \alpha \)-saracin between glutamine-27 and asparagine-28 to generate an N-terminal \( \beta \)-hairpin fragment and a C-terminal catalytic fragment (Fig. 1A). Our rationale to split \( \alpha \)-saracin at this site was that deletion of the N-terminal \( \beta \)-hairpin produces a catalytically active, but non-lethal fragment.\(^{14}\) The fact that the C-terminal fragment retains ribonuclease activity in the absence of the N-terminus implies that it can fold independently.\(^{14}\) Despite presumed autonomous folding of the fragments, our initial attempt at splicing was unsuccessful due to intolerance of the native extein sequence contributed by the NSar fragment. The MBP-VMA\(^N\)-FKBP and FRB-VMA\(^C\)-polyHis splicing constructs were critical to identifying the defect as a non-permissive NSar extein residue and provided an easy method to diagnose splicing deficiencies. Although placement of a glycine at the −1 position is not essential and can be substituted with other amino acid residues, there has been some selection for this residue in VMA intein.\(^{15}\) Substitutions at this position are thought to unfavorably shift the equilibrium of the splicing reaction.\(^{15}\) Fortunately, the Q27/G28C double mutation did not affect the toxicity of \( \alpha \)-saracin when directly expressed in the cytoplasm. Thus, with relatively minor changes it was possible to split \( \alpha \)-saracin into two fragments amenable to protein splicing. Strategies for evolving more promiscuous inteins that tolerate a greater diversity of extein sequences, as has been engineered for the Ssp. DnaB intein, should allow for easier adaptation of this method in the future.\(^{16}\) In addition to the contribution of extein sequence, we also confirmed temperature significantly affects splicing efficiency.\(^{11}\)

We chose the VMA split intein for this study because the \( N \) and \( C \)-terminal intein fragments show little self-association in the absence of a dimerizing agent.\(^{11,19}\) However, a major limitation to using the VMA intein was poor splicing at 37 °C. This appears to be contextual since the VMA intein/rapamycin-inducible system was previously shown to splice protein fragments at 37 °C in mammalian cells.\(^{11}\) In this instance, intact MBP and polyHis peptide were used as extein fragments and, therefore, similar folding challenges associated with splitting a native protein were not encountered. Evidence of the instability of our intein splicing constructs could be seen in the self-cleavage product of approximately 20 kDa that was detected by anti-FLAG immunoblotting. The presence of this species was decreased at 30 °C (Fig. 2B), suggesting improved stability at the lower temperature may account for the increase in splicing. The inability to splice at 37 °C currently restricts the applicability of our cell ablation strategy to cell culture or to organisms whose ambient temperature is 30 °C or lower. To overcome this limitation in the future, directed evolution could be applied to the VMA intein using NGFP-VMA\(^N\), CGFP-VMA\(^C\), and GFP fluorescence as a read out. A directed evolution strategy could also be used to improve the efficiency of splicing, which is currently about 70%. Indeed, several studies have
already utilized direction evolution to improve splicing of various inteins\(^{1,6,21,35}\) and we speculate our system can be improved by optimizing the intein sequence as well as the flanking \(\alpha\)-sarcin sequences.\(^{36-39}\) Alternatively, using different inteins in the context of the FKBP–FRB system may circumvent this problem.

Conclusions

We have tested whether protein splicing could be exploited to inducibly activate the protein toxin, \(\alpha\)-sarcin. After optimizing temperature and extein sequence parameters, we successfully spliced \(\alpha\)-sarcin in cultured mammalian cells. Splicing was rapidly induced and dosable with rapamycin concentration. Additionally, translation inhibition and apoptosis were initiated following splicing of \(\alpha\)-sarcin. These findings collectively provide a proof-of-concept for a conditional cell ablation strategy with potential applications in developmental biology or other studies requiring the rapid elimination of difficult-to-target quiescent populations of cells.

Acknowledgements

The authors thank Dr T. Muir for providing constructs containing the VMA intein fragments conjugated to the FRB and FKBP. This work was supported by a NSERC Discovery Grant awarded to PLH.

References

1. B. Fraser, M. G. DuVal, H. Wang and W. T. Allison, \textit{PLOS One}, 2013, \textbf{8}, e55410.
2. K. Araki, M. Araki and K. Yamamura, \textit{J. Biochem.}, 2006, \textbf{140}, 793–798.
3. M. Schuldiner, J. Itskovitz-Eldor and N. Benvenisty, \textit{Stem Cells}, 2003, \textbf{21}, 257–265.
4. S. Tanoue, P. Krishnan, B. Krishnan, S. E. Dryer and P. E. Hardin, \textit{Curr. Biol.}, 2004, \textbf{14}, 638–649.
5. M. Malecki, \textit{J. Genet. Syndr. Gene Ther.}, 2012, \textbf{3}, e114.
6. R. J. Kreitman and I. Pastan, \textit{Curr. Drug Targets}, 2006, \textbf{7}, 1301–1311.
7. D. Kirn, I. Niculescu-Duvaz, G. Hallden and C. J. Springer, \textit{Trends Mol. Med.}, 2002, \textbf{8}, S68–S73.
8. W. A. Denny, \textit{Cancer Invest.}, 2004, \textbf{22}, 604–619.
9. W. A. Denny, \textit{J. Biomed. Biotechnol.}, 2003, \textbf{1}, 48–70.
10. W. Cui, B. Gusterson and A. J. Clark, \textit{Gene Ther.}, 1999, \textbf{6}, 764–770.
11. H. D. Mootz, E. S. Blum, A. B. Tyszkiwicz and T. W. Muir, \textit{J. Am. Chem. Soc.}, 2003, \textbf{125}, 10561–10569.
12. S. Elleuch and S. Poggeler, \textit{Appl. Microbiol. Biotechnol.}, 2010, \textbf{87}, 479–489.
13. G. Amitai, B. P. Callahan, M. J. Stanger, G. Belfort and M. Belfort, \textit{Proc. Natl. Acad. Sci. U. S. A.}, 2009, \textbf{106}, 11005–11010.
14. M. Q. Xu and F. B. Perler, \textit{EMBO J.}, 1996, \textbf{15}, 5146–5153.
15. S. Chong, K. S. Williams, C. Wotkowicz and M. Q. Xu, \textit{J. Biol. Chem.}, 1998, \textbf{273}, 10567–10577.
16. J. H. Appleby-Tagoe, I. V. Thiel, Y. Wang, Y. Wang, H. D. Mootz and X. Q. Liu, \textit{Biol. Chem.}, 2011, \textbf{286}, 34440–34447.
17. D. D. Martin, M. Q. Xu and T. C. Evans Jr., \textit{Biochemistry}, 2001, \textbf{40}, 1393–1402.
18. T. C. Evans, Jr., D. Martin, R. Kolly, D. Panne, L. Sun, I. Ghosh, L. Chen, J. Benner, X. Q. Liu and M. Q. Xu, \textit{J. Biol. Chem.}, 2000, \textbf{275}, 9091–9094.
19. H. D. Mootz and T. W. Muir, \textit{J. Am. Chem. Soc.}, 2002, \textbf{124}, 9044–9045.
20. C. M. Yuen, S. J. Rodda, S. A. Vokes, A. P. McMahon and D. R. Liu, \textit{J. Am. Chem. Soc.}, 2006, \textbf{128}, 8939–8946.
21. S. H. Peck, I. Chen and D. R. Liu, \textit{Chem. Biol.}, 2011, \textbf{18}, 619–630.
22. A. Kanno, T. Ozawa and Y. Umezawa, \textit{Anal. Chem.}, 2006, \textbf{78}, 556–560.
23. T. Ozawa, S. Nogami, M. Sato, Y. Ohya and Y. Umezawa, \textit{Anal. Chem.}, 2000, \textbf{72}, 5151–5157.
24. T. Ozawa, A. Kaihara, M. Sato, K. Tachihara and Y. Umezawa, \textit{Anal. Chem.}, 2001, \textbf{73}, 2516–2521.
25. T. Ozawa, T. M. Takeuchi, A. Kaihara, M. Sato and Y. Umezawa, \textit{Anal. Chem.}, 2001, \textbf{73}, 5866–5874.
26. T. Sonntag and H. D. Mootz, \textit{Mol. Biosyst.}, 2011, \textbf{7}, 2031–2039.
27. S. S. Wong, I. Kotera, E. Mills, H. Suzuki and K. Truong, \textit{Cell Calcium}, 2012, \textbf{51}, 57–64.
28. J. C. Jennings, B. H. Olson, V. Roga, A. J. Junek and D. M. Schuurmans, \textit{Appl. Microbiol.}, 1965, \textbf{13}, 322–326.
29. Y. Endo, P. W. Huber and I. G. Wool, \textit{J. Biol. Chem.}, 1983, \textbf{258}, 2662–2667.
30. K. Eiklid, S. Olssen and A. Pihl, \textit{Exp. Cell Res.}, 1980, \textbf{126}, 321–326.
31. E. C. Schwartz, L. Saez, M. W. Young and T. W. Muir, \textit{Nat. Chem. Biol.}, 2007, \textbf{3}, 50–54.
32. S. C. Alford, J. D. Pearson, A. Carette, R. J. Ingham and P. L. Howard, \textit{BMC Biochem.}, 2009, \textbf{10}, 9, DOI: 10.1186/1471-2091010-9.
33. J. M. Perez-Canadillas, J. Santoro, R. Campos-Olivas, J. Lacadena, P. A. Martinez del, J. G. Gavilanes, M. Rico and M. Bruix, \textit{J. Mol. Biol.}, 2000, \textbf{299}, 1061–1073.
34. L. Garcia-Ortega, M. Masip, J. M. Manchano, M. Onaderra, M. A. Lizarbe, M. F. Garcia-Mayoral, M. Bruix, D. P. Martinez and J. G. Gavilanes, \textit{J. Biol. Chem.}, 2002, \textbf{277}, 18632–18639.
35. A. R. Buskirk, Y. C. Ong, Z. J. Gartner and D. R. Liu, \textit{Proc. Natl. Acad. Sci. U. S. A.}, 2004, \textbf{101}, 10505–10510.
36. M. W. Southworth, K. Amaya, T. C. Evans, M. Q. Xu and F. B. Perler, \textit{Biotechniques}, 1999, \textbf{27}, 110–120.
37. S. W. Lockless and T. W. Muir, \textit{Proc. Natl. Acad. Sci. U. S. A.}, 2009, \textbf{106}, 10999–11004.
38. S. Chong, G. E. Montello, A. Zhang, E. J. Cantor, W. Liao, M. Q. Xu and J. Benner, \textit{Nucleic Acids Res.}, 1998, \textbf{26}, 5109–5115.
39. H. Iwai, S. Zuger, J. Jin and P. H. Tam, \textit{FEBS Lett.}, 2006, \textbf{580}, 1853–1858.